Low-dose Rituximab in MS
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
Compared with
- Rituximab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
The primary endpoint, the annualized relapse rate, will be calculated during the final visit.
Relapses
Other measures (1)
- Annualized relapse rate at other time points (each infusion day)
Relapses
Who could take part
MS (type not specified)
Inclusion: • Signed informed consent obtained before any trial related activities Exclusion: • Patients with HepBc antibodies
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The main objective of this trial is to investigate whether 100mg rituximab every 10-12 weeks are equally effective compared to other, currently used dosing regimens. This will be evaluated by the annualized relapse rate at 48 weeks
Loading reviews and guidelines…
Related trials
- A Study of C-CAR168 in the Treatment of Autoimmune Diseas…
Phase 1 · Not yet recruiting
Still running
- CN46182
Phase 3 · Running, not recruiting
Still running
- Immune System Effects in Children Born to Women With Mult…
Not yet recruiting
Still running
- A Study of C-CAR168 in the Treatment of Central Nervous S…
Phase 1 · Not yet recruiting
Still running
- ML45855
Not a drug-phase study · Not yet recruiting
Still running
- B-cell Depletion in Offspring to Women With MS Under Immu…
Status unknown
No result found
History
Started
Mar 2018
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error